Eindhoven, the Netherlands – September 30, 2025 – At Sirius Medical, we are proud to announce the expansion of our collaboration with Mammotome, a global leader in breast care. Through an exclusive distribution agreement for our Pintuition® System in Italy and Poland, we are building on the successful partnership already established earlier this year in the United States and Germany
Breast cancer remains one of the greatest health challenges worldwide. That is why our mission is to support healthcare providers with technologies that improve surgical precision and enhance patient care. By introducing Surgical Marker Navigation, the Pintuition® System replaces conventional localization methods, enabling surgeons to remove tumors more simply, precisely, and efficiently.
“The successes we have achieved together in Germany and the United States demonstrate the strength of our collaboration,” said Jan Willem Beijer, Chief Commercial Officer of Sirius Medical. “We are excited to now bring these innovative solutions to Italy and Poland, supporting even more healthcare providers and their patients.”
Mammotome brings deep expertise in breast care and a strong sales network to these new markets, making them the ideal partner to further increase access to our technology.
“Our collaboration with Sirius Medical is built on mutual trust and a shared vision,” said Olaf Andrich, General Manager EMEA and APAC at Mammotome. “Expanding distribution to Italy and Poland is a natural next step and underscores our joint dedication to innovation and excellence in healthcare.”
Together with Mammotome’s broader portfolio — including the Neoprobe® Gamma Detection System and the HydroMARK™ Breast Biopsy Site Marker — we are now able to offer clinicians in Italy and Poland a comprehensive suite of premium solutions tailored to the evolving needs of breast surgery.
At Sirius Medical, we believe that collaboration is the key to progress. This new step brings us closer to our mission: empowering surgeons worldwide with smart, simple, and affordable navigation so patients can rely on the best possible care.
For more information about the Sirius Pintuition® System, please visit www.sirius-medical.com/Pintuition
For more information about Mammotome, visit Mammotome.com.
About Sirius Medical
With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivering unsurpassed yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition® technology is simple, precise, affordable, CE-marked, and FDA-cleared. Sirius Medical is rapidly expanding with over 35,000 procedures worldwide in more than 225 centers and a global commercial network covering the USA, Western Europe, Australia, and New Zealand.
About Mammotome
At Mammotome, our expertise and compassion for breast care makes us the indispensable partner to physicians, clinicians and patients. Our drive for innovation is rivaled only by our compassion for the people we serve, from the clinicians and surgeons who demand consistently precise solutions, to the patients and families seeking peace of mind. Headquartered in Cincinnati, OH, Mammotome is proud to be a part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. The Mammotome brand of products is sold in over 65 different countries throughout the world.
Media Contact:
Benjamin Tchang
Marketing Director
Sirius Medical
+31 647 852 805
Benjamin.tchang@sirius-medical.com
Erica Bednar
Marketing Communications Director
Mammotome
+1 513-391-4737
Erica.Bednar@Mammotome.com